knowledge -WSS

knowledge

author：entertainment 2025-10-01 22:57:40 - browse：8641

Sen. Rand Paul (C) (R-KY) questions Homeland Security Secretary Alejandro Mayorkas and FBI Director Christopher Wray during a hearing held by the Senate Homeland Security and Governmental Affairs Committee October 31, 2023 in Washington, DC. — Sen. Rand Paul (R-Ky.) Win McNamee/Getty Images

WASHINGTON — A Senate panel Wednesday passed a bill aimed at preventing certain Chinese companies from doing business in the United States. The sole no vote was by Sen. Rand Paul (R-Ky.), who worries that Congress is using anger toward China as a cover for advancing parochial interests.

Many in Congress are worried the Chinese government and military are using the rising dominance of national companies to gather Americans’ genetic information, which could be used for reasons that range from creating bioweapons to giving China a leg up in drug development.

The Biosecure Act, by Homeland Security and Governmental Affairs Chair Gary Peters (D-Mich.), is a response to those concerns. The bill would block the U.S. government from contracting with companies that do business with Chinese “biotechnology companies of concern,” and it names four companies that must be on that list: BGI Genomics, MGI, Complete Genomics, WuXi AppTec, and any subsidiary, parent affiliate, or successor of these companies.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： At least 13 dead in Texas as scorching temps continue
Next article： House GOP plan to stem drug shortages differs from Democrats’

hotspot

WSS

Clinicians often fail to acknowledge the pain caused by long Covid

The HPV vaccine prevents cancer in men, too. Why do so few people get it?

Richard Slayman had a rejection episode of his pig kidney before leaving hospital

J&J reports mixed data on next

Fla. should 'correct' controversial slavery curriculum: Republican Rep. Byron Donalds

Lawsuit challenges CMS nursing home minimum staffing rule

explore

knowledge

knowledge

How to save PrEP access — and even expand it

Clinicians often fail to acknowledge the pain caused by long Covid

Trump demands the U.S. pay no more for drugs than other countries … again

Japan raises alarm over China's military, Russia ties and Taiwan tensions in new defense paper

Apple is now the first public company to be valued at $3 trillion

Unmasking the 'centricity' illusion in clinical trials

FDA approval of Sarepta Duchenne genetic therapy gives me hope

Duchenne drug from Nippon Shinyaku fails in rare confirmatory trial

State Dept. review finds Biden bears some blame for Afghanistan failures

Guardant Health colon cancer test endorsed by FDA advisory panel

entertainment

Achieving telehealth equity for people with hearing loss

Guardant Health colon cancer test endorsed by FDA advisory panel

HCA says smaller share of spending going to labor

U.S. death rates show how politics are affecting public health

Congress: Prevent baby formula shortages by passing a new bill

Europe is fastest

focus

hotspot

focus

focus